# Altus Capital Partners

> Altus Capital Partners is a VC fund backing Health Care and Therapeutics. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Wilton, United States
- Total investments: 1
- Last investment: Mar 2017
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.altuscapitalpartners.com

Altus Capital Partners is a VC fund in Wilton focused on Health Care and Therapeutics. Altus Capital Partners is recognized for its deep knowledge and commitment to American manufacturers with proprietary technologies. They have a proven track record in building value through buyouts, recapitalizations, divestitures and consolidations.

## Contacts

5 contacts available for Altus Capital Partners. Shizune tracks 3 team members at Altus Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/altus-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 100% |
| Therapeutics | 1 | 100% |
| Pharmaceutical | 1 | 100% |
| Health Diagnostics | 1 | 100% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Joshua Tesoriero | Vice President | 0 | — |
| Nick DeMarco | Principal | 0 | — |
| Tom Groh | Partner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Versantis | Versantis is a Swiss pharmaceutical company, Spin-off of ETH Zurich, developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide. Its lead candidate, VS-01, iscurrently at preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis. | $5.1M | Series A | Mar 29, 2017 |  |

1 of 1 investments shown.

## Co-investors
- [Healthequity](https://shizune.co/investors/profile/healthequity-2) — VC Fund, 1 deal together
- [MassChallenge](https://shizune.co/investors/profile/masschallenge) — VC Fund, 1 deal together
- [OCCIDENT](https://shizune.co/investors/profile/occident-group) — VC Fund, 1 deal together
- [redalpine](https://shizune.co/investors/profile/redalpine-venture-partners) — VC Fund, 1 deal together
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Altus Capital Partners invest in?

Altus Capital Partners invests primarily in Health Care, Therapeutics and Pharmaceutical startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Altus Capital Partners?

Public channels for Altus Capital Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Altus Capital Partners?

The team at Altus Capital Partners includes Joshua Tesoriero (Vice President), Nick DeMarco (Principal) and Tom Groh (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co